175 related articles for article (PubMed ID: 37046684)
1. Prognostic Value of Inflammatory and Nutritional Biomarkers of Immune Checkpoint Inhibitor Treatment for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.
Sakai A; Iijima H; Ebisumoto K; Yamauchi M; Teramura T; Yamazaki A; Watanabe T; Inagi T; Maki D; Okami K
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046684
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy following immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: clinical effectiveness and influence of inflammatory and nutritional factors.
Sakai A; Ebisumoto K; Iijima H; Yamauchi M; Teramura T; Yamazaki A; Watanabe T; Inagi T; Maki D; Okami K
Discov Oncol; 2023 Aug; 14(1):158. PubMed ID: 37642856
[TBL] [Abstract][Full Text] [Related]
3. Inflammation-based Prognostic Score as a Prognostic Biomarker in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With Nivolumab Therapy.
Matsuo M; Yasumatsu R; Masuda M; Toh S; Wakasaki T; Hashimoto K; Jiromaru R; Manako T; Nakagawa T
In Vivo; 2022; 36(2):907-917. PubMed ID: 35241549
[TBL] [Abstract][Full Text] [Related]
4. Ultra-high combined positive score and high serum albumin are favorable prognostic biomarkers for immune checkpoint inhibitors in head and neck squamous cell carcinoma.
Saito Y; Kobayashi K; Fukuoka O; Sakai T; Yamamura K; Ando M; Kondo K
Head Neck; 2024 Feb; 46(2):367-377. PubMed ID: 38063247
[TBL] [Abstract][Full Text] [Related]
5. Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients.
Chalker C; Voutsinas JM; Wu QV; Santana-Davila R; Hwang V; Baik CS; Lee S; Barber B; Futran ND; Houlton JJ; Laramore GE; Liao JJ; Parvathaneni U; Martins RG; Eaton KD; Rodriguez CP
Cancer Med; 2022 Nov; 11(22):4104-4111. PubMed ID: 35349227
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
[TBL] [Abstract][Full Text] [Related]
7. Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor.
Chen Y; Zhang C; Peng Z; Qi C; Gong J; Zhang X; Li J; Shen L
Front Oncol; 2021; 11():589022. PubMed ID: 34141607
[TBL] [Abstract][Full Text] [Related]
8. The Geriatric Nutritional Risk Index (GNRI) as a Prognostic Biomarker for Immune Checkpoint Inhibitor Response in Recurrent and/or Metastatic Head and Neck Cancer.
Haas M; Lein A; Fuereder T; Brkic FF; Schnoell J; Liu DT; Kadletz-Wanke L; Heiduschka G; Jank BJ
Nutrients; 2023 Feb; 15(4):. PubMed ID: 36839241
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma.
Starzer AM; Heller G; Tomasich E; Melchardt T; Feldmann K; Hatziioannou T; Traint S; Minichsdorfer C; Schwarz-Nemec U; Nackenhorst M; Müllauer L; Preusser M; Berghoff AS; Fuereder T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338086
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil-to-Lymphocyte Ratio to Predict the Efficacy of Immune Checkpoint Inhibitor in Upper Gastrointestinal Cancer.
Booka E; Kikuchi H; Haneda R; Soneda W; Kawata S; Murakami T; Matsumoto T; Hiramatsu Y; Takeuchi H
Anticancer Res; 2022 Jun; 42(6):2977-2987. PubMed ID: 35641297
[TBL] [Abstract][Full Text] [Related]
11. Utility of prognostic nutritional index and systemic immune-inflammation index in oral cancer treatment.
Kubota K; Ito R; Narita N; Tanaka Y; Furudate K; Akiyama N; Chih CH; Komatsu S; Kobayashi W
BMC Cancer; 2022 Apr; 22(1):368. PubMed ID: 35392843
[TBL] [Abstract][Full Text] [Related]
12. Prognostic implications of preoperative systemic inflammatory markers in oral squamous cell carcinoma, and correlations with the local immune tumor microenvironment.
Ruiz-Ranz M; Lequerica-Fernández P; Rodríguez-Santamarta T; Suárez-Sánchez FJ; López-Pintor RM; García-Pedrero JM; de Vicente JC
Front Immunol; 2022; 13():941351. PubMed ID: 35958590
[TBL] [Abstract][Full Text] [Related]
13. Pretherapeutic nutritional/inflammatory factors as predictors for survival of both early and advanced staged head and neck cancer patients.
Yamahara K; Mizukoshi A; Lee K; Ikegami S
Auris Nasus Larynx; 2021 Aug; 48(4):731-737. PubMed ID: 33261982
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of combined preoperative platelet-to-lymphocyte ratio and lymphocyte-to-monocyte ratio in patients undergoing surgery with stage IB non-small-cell lung cancer.
Chen Y; Wang W; Zhang X; Yu X; Xi K; Wen Y; Wang G; Feng X; Zhang L
Cancer Manag Res; 2018; 10():5411-5422. PubMed ID: 30519089
[TBL] [Abstract][Full Text] [Related]
15. Inflammation-related parameter serve as prognostic biomarker in esophageal squamous cell carcinoma.
Xu X; Jing J
Front Oncol; 2022; 12():900305. PubMed ID: 36338698
[TBL] [Abstract][Full Text] [Related]
16. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
Song A; Eo W; Lee S
World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
[TBL] [Abstract][Full Text] [Related]
17. Systemic immune response in squamous cell carcinoma of the head and neck: a comparative concordance index analysis.
Tham T; Wotman M; Chung C; Ahn S; Dupuis H; Gliagias V; Movsesova T; Kraus D; Costantino P
Eur Arch Otorhinolaryngol; 2019 Oct; 276(10):2913-2922. PubMed ID: 31312922
[TBL] [Abstract][Full Text] [Related]
18. Cachexia index in predicting outcomes among patients receiving immune checkpoint inhibitor treatment for metastatic renal cell carcinoma.
Aslan V; Kılıç ACK; Sütcüoğlu O; Eraslan E; Bayrak A; Öksüzoğlu B; Tahtacı G; Özdemir N; Üner A; Günel N; Özet A; Yazıcı O
Urol Oncol; 2022 Nov; 40(11):494.e1-494.e10. PubMed ID: 36137881
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
Wakasaki T; Yasumatsu R; Masuda M; Takeuchi T; Manako T; Matsuo M; Jiromaru R; Uchi R; Komune N; Noda T; Nakagawa T
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32824226
[TBL] [Abstract][Full Text] [Related]
20. Different inflammatory blood markers correlate with specific outcomes in incident HPV-negative head and neck squamous cell carcinoma: a retrospective cohort study.
Boscolo-Rizzo P; D'Alessandro A; Polesel J; Borsetto D; Tofanelli M; Deganello A; Tomasoni M; Nicolai P; Bossi P; Spinato G; Menegaldo A; Ciorba A; Pelucchi S; Bianchini C; Cazzador D; Ramaciotti G; Lupato V; Giacomarra V; Molteni G; Marchioni D; Fabbris C; Occhini A; Bertino G; Fussey J; Tirelli G
BMC Cancer; 2022 Mar; 22(1):243. PubMed ID: 35248020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
